Mouse RAGE/AGER Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB11795
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Gly23-Leu342
Accession # NP_031451
Specificity
Clonality
Host
Isotype
Scientific Data Images for Mouse RAGE/AGER Antibody
Detection of Mouse and Rat RAGE by Western Blot.
Western blot shows lysates of mouse lung tissue, Neuro-2A mouse neuroblastoma cell line, and rat lung tissue. PVDF membrane was probed with 1 µg/mL of Rat Anti-Mouse RAGE Monoclonal Antibody (Catalog # MAB11795) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (HAF005). Specific bands were detected for RAGE at approximately 45 to 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Detection of RAGE in Mouse Splenocytes by Flow Cytometry.
Mouse splenocytes stimulated to induce Th1 cells were stained with Rat Anti-Mouse CD4 PE-conjugated Monoclonal Antibody (FAB554P) and either (A) Rat Anti-Mouse RAGE Monoclonal Antibody (Catalog # MAB11795) or (B) Rat IgG2AIsotype Control (MAB006) followed by Allophycocyanin-conjugated Anti-Rat IgG Secondary Antibody (F0113). View our protocol for Staining Membrane-associated Proteins.Detection of Mouse AGER by Immunocytochemistry/Immunofluorescence
Treatment with anti-M7 prevents inflammatory leukocyte recruitment in vitro and in vivo. a Murine peritoneal macrophages were incubated on dishes coated with mouse CD40L in the presence of 10μg/ml of IgG, anti-M7, or anti-Mac-1 (clone M1/70). Adhering cells were normalized to % of the IgG-treatment. b Murine RAW-cell adhesion on TNF alpha-primed murine endothelial cells under physiological flow in the presence of IgG or anti-M7 antibodies (10 μg/ml). c–f C57Bl/6 mice were injected i.p. with 200 ng TNF alpha and 15 min before microscopy with Fab fragments of an IgG control antibody, or antibodies against RAGE, ICAM-1, LFA-1, Mac-1 (clone M1/70), or anti-M7 (100 μg i.p.). Leukocyte recruitment was monitored by intravital microscopy 4 h later: Adhering (d) and rolling leukocytes (e) were quantified as % of IgG. (f) Cumulative frequency of leukocyte rolling velocity. g Leukocyte adhesion in intravital microscopy in IgG or anti-M7 treated WT and Mac-1−/− mice. h, i Number of CX3CR1-GFP+ monocytes (white arrows) in the para-vascular space 4 h after treatment with IgG or anti-M7 and 200ng TNF alpha. j Confocal in vivo imaging of the greater omentum after local stimulation with TNF alpha and i.v. injection of the indicated antibodies (100 μg) in LysM-GFP reporter mice. LysM-GFP+ myeloid cells were tracked over time. Time lapse and cell tracking is shown over 15 min (right panel). k Plasma cytokine levels of mice subjected to intravital microscopy after IgG or anti-M7 Fab treatment. l Peritoneal exudate cells (PECs) 72 h after induction of a sterile peritonitis and the indicated antibody treatment. Scale bars represent 100μm (c, h, j). Error bars indicate mean ± SEM. Statistical significance was assessed by a two-sided, unpaired Student’s T-test between the indicated groups (a, b, g, i, k, l) or in comparison to IgG-treatment (d, e). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. N ≥ 3 independent experiments (a, b). N ≥ 10 mice per group (d, e, f, g), N ≥ 6 mice per group (l, h) Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29410422), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Mouse RAGE/AGER Antibody
CyTOF-ready
Flow Cytometry
Sample: "HEK293 human embryonic kidney cell line transfected with mouse RAGE/AGRE" vs. "wild HEK293 human embryonic kidney cell line "
Western Blot
Sample: Mouse lung tissue, Neuro‑2A mouse neuroblastoma cell line, and rat lung tissue
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: RAGE/AGER
Advanced glycation endproducts (AGE) are adducts formed by the non-enzymatic glycation or oxidation of macromolecules (1). AGE forms during aging and its formation is accelerated under pathophysiologic states such as diabetes, Alzheimer’s disease, renal failure and immune/inflammatory disorders. Receptor for Advanced Glycation Endoproducts (RAGE), named for its ability to bind AGE, is a multiligand receptor belonging the immunoglobulin (Ig) superfamily. Besides AGE, RAGE binds amyloid beta-peptide, S100/calgranulin family proteins, high mobility group B1 (HMGB1, also know as amphoterin) and leukocyte integrins (1, 2).
The mouse RAGE gene encodes a 403 amino acid (aa) residue type I transmembrane glycoprotein with a 22 aa signal peptide, a 319 aa extracellular domain containing a Ig-like V-type domain and two Ig-like Ce-type domains, a 21 aa transmembrane domain and a 41 aa cytoplasmic domain (3). The V-type domain and the cytoplasmic domain are important for ligand binding and for intracellular signaling, respectively. Two alternative splice variants, lacking the V-type domain or the cytoplasmic tail, are known (1, 4). RAGE is highly expressed in the embryonic central nervous system (5). In adult tissues, RAGE is expressed at low levels in multiple tissues including endothelial and smooth muscle cells, mononuclear phagocytes, pericytes, microglia, neurons, cardiac myocytes and hepatocytes (6). The expression of RAGE is upregulated upon ligand interaction. Depending on the cellular context and interacting ligand, RAGE activation can trigger differential signaling pathways that affect divergent pathways of gene expression (1, 7). RAGE activation modulates varied essential cellular responses (including inflammation, immunity, proliferation, cellular adhesion and migration) that contribute to cellular dysfunction associated with chronic diseases such as diabetes, cancer, amyloidoses and immune or inflammatory disorders (1).
References
- Schmidt, A. et al. (2001) J. Clin. Invest. 108:949.
- Chavakis, T. et al. (2003) J. Exp. Med. 198:507.
- Renard, C. et al. (1997) Mol. Pharmacol. 52:54.
- Yonekura, H. et al. (2003) Biochem. J. 370:1097.
- Hori, O. et al. (1995) J. Biol. Chem. 270:25752.
- Brett, J. et al. (1993) Am. J. Pathol. 143:1699.
- Valencia, J.V. et al. (2004) Diabetes 53:743.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional RAGE/AGER Products
Product Documents for Mouse RAGE/AGER Antibody
Product Specific Notices for Mouse RAGE/AGER Antibody
For research use only